# The Heterogeneity and Function of Stromal Cells in the Tumor Microenvironment

## TL;DR

This review explores how stromal cells in the tumor environment actively influence cancer progression and treatment resistance, highlighting the need for targeted therapies.

## Contribution

The paper emphasizes the importance of stromal heterogeneity and proposes subtype-specific biomarkers and therapies to combat stromal-mediated resistance.

## Key findings

- Stromal cells are heterogeneous and actively regulate tumor behavior through molecular programs and spatial niches.
- Cytokine networks like TGF-beta and IL-6 coordinate processes such as epithelial-mesenchymal transition and angiogenesis.
- Integrating stromal heterogeneity into precision oncology can improve diagnostics and personalized treatment strategies.

## Abstract

The tumor microenvironment is a central determinant of cancer progression, metastatic spread, and therapeutic resistance. Once considered passive scaffolds, stromal cells are now recognized as heterogeneous, active regulators of tumor behavior. Recent single-cell and spatial multiomics studies have resolved functionally distinct stromal subtypes, each defined by characteristic molecular programs and spatial niches, with specialized roles in extracellular matrix remodeling, immune evasion, and angiogenesis. This review synthesizes evidence for bidirectional stromal–tumor cross-talk in which cytokine networks (e.g., transforming growth factor-beta, interleukin-6, and C-X-C motif chemokine ligand 12/C-X-C chemokine receptor 4) coordinate epithelial–mesenchymal transition, stemness, chemotaxis, and vascular remodeling. Building on these insights, this review also argues for subtype-specific biomarkers and multimodal therapeutic strategies to overcome stromal-mediated resistance. Integrating stromal heterogeneity into precision-oncology workflows through standardized, lineage-resolved profiling and real-time biomarker guidance will be essential for diagnostic refinement and personalized treatment.